[adrotate group="2"]

Market Mayhem? Not For These Hot Medical Stocks!

Are You Missing Out? These Mid-Cap Stocks Are Killing It While Others Flounder!

While the big names on Wall Street are struggling, a trio of mid-cap medical stocks is soaring! Investors looking for diamonds in the rough can find solid gold in companies that are defying the odds. Forget the large-cap giants—here’s where the action is in 2025!

1. Penumbra: The Unstoppable Med-Tech Star!

Hold onto your hats! Penumbra Inc (NYSE: PEN) is CRUSHING it in the world of medical devices, catapulting to an astonishing 23% gain this year alone and a jaw-dropping 43% over the last 12 months! This $11.3 billion powerhouse is at the top of its game, riding the wave of innovation in neuro and vascular interventions.

Just recently, Penumbra dropped some serious earnings news—$0.83 per share, blowing past expectations by $0.17! Their revenues surged 16.3% year-over-year, reaching $324.1 million, and still, they’re riding high, just a whisker away from their all-time peak. Analysts can’t get enough, with a “Moderate Buy” buzz and a price target promising even more upside!

2. TransMedics Group: The Game-Changer in Organ Transplants!

You won’t believe what TransMedics Group Inc (NASDAQ: TMDX) is doing! This trailblazing med-tech giant is shaking up organ transplant procedures with its mind-blowing Organ Care System (OCS). Talk about a lifesaver! Their stock has skyrocketed nearly 48% this year, especially after blasting past key resistance levels.

Sure, their high P/E ratio of 91 might raise some eyebrows, but the forward P/E of 41 suggests STRONG earnings growth is on the horizon! And with a Moderate Buy consensus rating from all eleven analysts covering the stock—touting a price target that screams 35% upside—you’d be crazy to look away!

3. ADMA Biologics: The Biotech Beast Ready for Takeoff!

Get ready for the next big biotech success story! ADMA Biologics Inc (NASDAQ: ADMA) is on FIRE, with shares up a remarkable 38% year-to-date! This biopharmaceutical powerhouse specializes in plasma-derived biologics that tackle immune deficiencies and infectious diseases.

Sitting just 7% below its all-time high and gearing up for an earnings report on May 7, the excitement is palpable! With a P/E of 29 and a forward P/E of 23—plus an expected 45% EPS growth in 2025—ADMA is a stock to watch! Four enthusiastic analysts are backing it as a Buy, firmly positioning this company for even greater heights!

Don’t Get Left Behind!

As major indexes struggle, these mid-cap medical stocks are blazing trails and delivering results! Whether you’re a seasoned investor or just getting your feet wet, these companies are where you want your money to be. Get in now before the momentum leaves you in the dust!